TrumpRx in Focus: Assessing the Implications for Pharma Manufacturers 

Our previous article explored how TrumpRx might influence drug pricing in the US, the potential connection to MFN pricing, and how the initiative could operate in practice. This follow-up article shifts the focus to what TrumpRx means specifically for pharmaceutical manufacturers, examining the commercial, strategic, and policy implications from an industry perspective. 

Participating Manufacturers on the TrumpRx Platform 

The direct-to-consumer (DTC) channel, launched on 5 February, initially featured around 40 products from five manufacturers that agreed pricing arrangements with the Trump Administration under MFN-linked voluntary, including AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer¹. 

Since launch, participation has expanded significantly, with most large pharmaceutical companies now having signed MFN-linked agreements, and additional manufacturers such as Amgen and GSK joining the platform². 

Additional drugs are not only expected but are already being added post-launch, reflecting ongoing expansion in both manufacturer participation and product availability². 

Types of Medicines Included on the Platform  

The included drugs cover a broad range of therapeutic areas, encompassing: 

• Metabolic and endocrine therapies such as semaglutide products for diabetes and weight loss (for example, Wegovy and Ozempic) and tirzepatide (Zepbound).  

• Fertility treatments and reproductive medicines including gonadotrophins and antagonists like Gonal-F and Cetrotide.  

• Diabetes medications such as insulin lispro and Xigduo XR.   

• Cardiovascular and lipid agents including Colestid and Lopid.  

• Respiratory medicines such as Airsupra and Bevespi.  

• Thyroid and hormone therapies like Cytomel and Levoxyl, along with women’s health products such as Premarin formulations.  

• Autoimmune and inflammatory agents (Xeljanz, Abrilada, Medrol).  

• Antibiotics, antifungals and antivirals, for example Zyvox, Diflucan, Vfend and Viracept.  

• Other classes covering smoking cessation (Chantix and Nicotrol), neurological or psychiatric drugs (Zarontin, Pristiq), bladder control (Toviaz) and migraine treatment (Zavzpret) 

At launch, approximately 43 drugs were listed on the platform, this has since increased to approximately 54 medicines as of March 2026^2,3.  

What the drug selection reveals? 

The composition of drugs currently appears to be commercially curated rather than therapeutically targeted. Inclusion seems driven by manufacturer negotiation dynamics and willingness to expose selected assets to structured cash pricing. In practice, this often aligns with products that are already supported by manufacturer-led direct-to-consumer access channels.  

For example, users attempting to order Zepbound via TrumpRx are redirected to LillyDirect, illustrating that the platform can function as a routing mechanism to existing manufacturer infrastructure rather than a standalone purchasing channel. 

However, early critiques also suggest that, in some cases, lower prices may already be available through existing channels such as generics or insurance coverage, raising questions about the platform’s true impact for patient access and affordability⁴. 

What this means for pharma manufacturers 

For pharmaceutical manufacturers, early indications suggest that TrumpRx is unlikely to have a major long-term impact on earnings and US pricing, as inclusion on the platform alone does not directly affect any of the underlying pricing framework. Specifically: 

• It does not materially alter negotiated net prices agreed with PBMs and payers 

• It does not create a new statutory reference price  

• It does not integrate into existing PBM contracting structures or Medicare payment formulae 

Importantly, TrumpRx is currently limited to cash-paying patients and cannot be used in conjunction with insurance or count toward deductibles, significantly constraining its addressable population and limiting its direct commercial impact².  

On the other hand, one could also argue that in cases where users are redirected to manufacturer-led direct-to-consumer platforms, the model can channel increased volume through company-controlled distribution pathways.  

For example, where TrumpRx redirects patients to a manufacturer’s own DTC infrastructure, and purchasing occurs outside traditional PBM adjudication. This can allow manufacturers to: 

• Avoid intermediary rebates and associated margin leakage 

• Capture a greater share of the transaction economics 

• Improve pricing transparency and predictability 

• Strengthen direct patient engagement  

While these channel-level dynamics may offer small tactical advantages for participating manufacturers on a select few assets, the broader significance of TrumpRx may lie less in its mechanics than in the attention it is attracting.  

TrumpRx Optics or Reform? 

TrumpRx has once again turned the spotlight on drug pricing reform, a rare area that continues to command broad bipartisan support, even if there is less agreement on the best ways to do it. While the platform itself may not materially alter the underlying pricing framework, the visibility and rhetoric surrounding it may prove more consequential.  

This is reinforced by the design and presentation of the website itself, which places bold, highly visible political messaging at the forefront, signalling that shaping the public narrative is a central component of TrumpRx.  

Alongside the highly publicised MFN deals, the launch of TrumpRx reinforces that addressing US drug pricing remains firmly in the spotlight for this administration. However, only time will tell whether this noise can actually translate into long-term, durable reform that materially alters the commercial outlook for pharmaceutical manufacturers and reshapes the industry’s pricing and revenue model in the US and beyond. 

To further explore what these developments could mean for your portfolio and ensure your pricing launch strategy remains ahead of the curve for an ever-changing environment, contact our expert team here! 

References:  

1. NBC News. Trump Launches Discount Drug: What to Know. NBC News, 2026, https://www.nbcnews.com/health/health-news/trumprx-launch-discount-drug-what-know-rcna257549 
2. Fierce Pharma. Meds from Amgen, GSK now offered through TrumpRx DTC platform, 2026, https://www.fiercepharma.com/pharma/meds-amgen-gsk-join-fold-drugs-offered-through-governments-trumprx-dtc-platform 
3. American Progress. TrumpRx discounts only one drug while 22 million Americans see costs rise. Center for American Progress, 2026, https://www.americanprogress.org/article/trumprx-discounts-only-one-drug-while-22-million-americans-see-costs-rise 
4. Washington Post Intelligence. TrumpRx’s price problem. Washington Post, 2026, https://www.washingtonpost.com/wp-intelligence/health-brief/2026/02/06/trumprxs-price-problem